Filing summary
Issuer and period: The supplied filing is IMARA Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2021. This does not match the requested company, Enliven Therapeutics, Inc.; verify the issuer before relying on this summary.
Business context and financial results
IMARA was a clinical-stage biotechnology company with no approved products or product revenue. Its lead candidate, tovinontrine (IMR-687), was in development for sickle cell disease (SCD) and beta-thalassemia. The company reported operating expenses and losses; conventional gross margins were not applicable.
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $10.4 million | $9.5 million | $27.6 million | $23.2 million |
| General and administrative expense | $3.3 million | $3.0 million | $9.5 million | $7.0 million |
| Net loss | $13.6 million | $12.4 million | $37.1 million | $29.8 million |
| Net loss per share | $0.55 | $0.72 | $1.84 | $2.97 |
| Cash used in operations | Not stated for quarter | Not stated for quarter | $34.3 million | $29.1 million |
At September 30, 2021, cash and cash equivalents were $75.3 million and short-term investments were $27.5 million, totaling approximately $102.8 million. Total current assets were $106.0 million and current liabilities $7.2 million. Total liabilities were $7.7 million; the balance sheet reported no debt. Accumulated deficit was $133.2 million.
Changes and financing
- Nine-month operating expenses rose $7.0 million year over year, driven by higher clinical development and manufacturing costs for tovinontrine, increased headcount and public-company costs.
- Nine-month net loss increased $7.2 million year over year. Lower interest income partly offset the higher expenses.
- In July 2021, IMARA sold 8.33 million common shares at $6.00 per share, receiving approximately $46.8 million net. ATM sales generated a further approximately $1.5 million net through September 30. Shares outstanding increased to 26.28 million from 17.55 million at year-end 2020.
- Operating lease right-of-use assets and lease liabilities were recognized following adoption of ASC 842; the filing said adoption did not materially affect results of operations.
Outlook, commentary and risks
- Management expected available cash, cash equivalents and investments to fund operations into the first quarter of 2023, while warning that estimates depend on assumptions and additional funding would be needed. The liquidity note separately says funds were expected to cover at least 12 months from the filing date; verify this difference in runway wording.
- Management expected significant operating losses and research and development costs to continue. The company had no committed external funding source and might need equity, debt, collaboration or licensing financing, potentially dilutive or on unfavorable terms.
- Ardent, a Phase 2b SCD trial, had completed enrollment. Management expected interim data in Q4 2021, primary-analysis data in Q1 2022 and final-analysis data in the second half of 2022. Forte, a Phase 2b beta-thalassemia trial, had completed enrollment in its transfusion-dependent arm; enrollment in the non-transfusion-dependent arm continued. Data readouts were planned across late 2021 and 2022.
- Management expected to begin a Phase 2 HFpEF trial in 2022, subject to its development plan and regulatory engagement. IMR-261 research and manufacturing work had begun, but it was not in clinical development.
- COVID-19 had caused missed or delayed patient visits, site activation and enrollment delays, and delays in regulatory-submission review. Key risks include clinical and regulatory uncertainty, reliance on tovinontrine, surrogate-endpoint acceptance, limited patient populations, competition, third-party manufacturing dependence, intellectual-property exposure and financing needs.
- The filing reported no material pending or threatened legal proceedings. It also disclosed November 5, 2021 amendments to CEO and CFO/COO change-of-control severance arrangements.
Most important facts to verify
- Confirm the issuer: this filing identifies IMARA Inc., not Enliven Therapeutics, Inc.
- Reconcile the stated cash runway: into Q1 2023 in MD&A versus at least 12 months from filing in the liquidity note.
- Check actual trial readouts and any subsequent changes to Ardent, Forte and HFpEF timelines, including the impact of COVID-19.
- Assess cash burn, financing availability and dilution after the July 2021 offering; the runway was management’s estimate, not a guarantee.
- Evaluate whether clinical endpoints, particularly HbF as a potential surrogate in SCD, can support meaningful benefit and regulatory approval.